Choosing where to submit your chemistry manuscript is rarely a clean decision. You weigh scope. You weigh prestige. And — almost always — you check the impact factor before you do anything else. The American Chemical Society publishes more than 80 peer-reviewed journals, and their impact factors swing from under 2 to over 60 depending on the title and the year.

This page is a working directory. We'll lay out the most recent JCR cycle data for the journals chemists actually submit to, then walk through what those numbers really mean — and where they fall apart. If you've ever stared at a list of ACS journal impact factors wondering which one matches your work, you're in the right place.

Quick reminder before we dig in. Impact factor is calculated by Clarivate's Journal Citation Reports (JCR), released each summer for the prior two publication years. The 2024 JCR cycle (published mid-2024) covers citations to articles from 2022 and 2023 — that's the data you'll see referenced across this guide. Newer journals (those founded after roughly 2020) sometimes don't yet have a stable impact factor, since they need two full publication years of indexed content before Clarivate calculates a value.

Why does this matter beyond bragging rights? Three reasons. Career evaluators still glance at these numbers when they're flipping through your CV. Funding agencies in many countries still tie tier-1 publications to grant scoring rubrics. And — most practically — the impact factor tells you something real about how often the average paper in that venue ends up cited, which is a rough proxy for how visible your own work will be once it's published there.

One thing we'll keep repeating throughout this guide: impact factor is a coarse signal, not a precision tool. Use it the way you'd use a thermometer in cooking — directionally useful, not the only thing that matters.

Let's start where most chemists do: the headline numbers. ACS's flagship titles compete with Nature-family journals, while their broad-scope titles like ACS Omega are pitched as fast, open-access alternatives to bigger names. The impact factors below tell you, at a glance, how often the average paper in each journal got cited in the JCR cycle that closed in 2024.

Don't read the table as a ranking. Read it as a snapshot. A 9.0 impact factor in a materials journal isn't comparable to a 9.0 in a biochemistry journal — citation cultures vary wildly across subfields. Chemistry, generally, sits in the middle: higher than pure math, lower than clinical medicine. So a strong ACS specialty journal hitting 10+ is genuinely strong work, even though that number would look modest in a clinical research category.

A few other numbers worth memorizing if you work in chemistry. Inorganic Chemistry sits around 4. Organometallics sits around 4. Journal of Organic Chemistry sits around 3.5. Analytical Chemistry sits around 7. These aren't headline numbers, but they're respected Q1 journals in their subject categories — and a paper in any of them tells reviewers that you write tightly-scoped, technically clean chemistry.

The newer entries in the ACS catalog deserve attention too. JACS Au (the open-access companion to JACS) launched in 2021 and is climbing fast. ACS Catalysis Au, ACS Materials Au, and a handful of other "Au" titles followed. Their impact factors are still settling, but the editorial standards mirror their parent journals — useful homes when you need open access without leaving the ACS ecosystem.

Some authors fixate on the absolute number. Bad habit. What matters more is where a journal sits inside its category. Clarivate ranks every journal in JCR by quartile — Q1 means top 25% of its subject category, Q4 means bottom 25%. A Q1 journal with an impact factor of 6 often signals higher selectivity than a Q2 journal sitting at 9 in a more citation-heavy field. Quartiles normalize across subject categories in a way that absolute impact factors never do.

The other dimension worth tracking: trajectory. ACS Energy Letters launched in 2016 and climbed past 22 within seven years. That kind of climb tells you the editorial team is curating tightly and the field itself is exploding. Compare that to long-established titles like Inorganic Chemistry, which sits around 4 — respected, broad, stable, but not a meteor. Both are useful. They just signal different things on a CV.

A practical move: pull up the journal's five-year impact factor alongside its two-year number. Clarivate publishes both. If the five-year is meaningfully higher than the two-year, the journal's citation half-life is long — typical for methods-heavy or theory-heavy work. If the two-year is higher, citations spike fast and fade fast, which is common in hot application areas. Either pattern is fine. Knowing which one you're looking at saves you from misreading a single year's snapshot.

So how do you actually use these numbers? Three honest applications, in order of usefulness.

First, calibrate scope. If your finding feels like a JACS-tier mechanism story but you're shopping it to ACS Omega because "the impact factor's fine," you're probably underselling. Reverse is also true — a methods paper aimed at a 60+ impact factor review journal is a long shot, and you'll waste months in desk-rejection cycles. Scope match beats impact factor chase every single time.

Second, gauge competition. Higher impact factor usually correlates with higher rejection rates. ACS Nano rejects somewhere north of 70% of submissions. Chemical Reviews is invitation-driven for most issues. Knowing that upfront saves you the sting of a fast desk-reject email at 11 PM. Build a realistic submission plan — first-choice journal, two backups in descending order of selectivity, and a clear "we'll just publish it" venue at the bottom of the list.

Third, signal to evaluators. Like it or not, hiring committees, grant panels, and tenure reviewers still glance at the impact factor of where you publish. That's changing — slowly — but it's still the reality in 2025 and 2026. The signal is strongest in your first three to five publications as an independent investigator, and fades as your full record speaks for itself.

A fourth, more subtle application: impact factor is a coarse signal of reach. A paper in a 20+ IF journal reaches a broader audience by default than the same paper in a 4-IF journal. That matters if your work has implications beyond your immediate subfield. It matters less if you're publishing for a tightly-defined community that reads two or three specialty journals anyway.

Now for the cracks in the system. Impact factor has real, well-documented problems, and any researcher using it as a sole metric is going to get burned eventually.

The math is skewed. A single highly-cited paper can drag a journal's impact factor up 30%. Editors know this, and you'll occasionally see a low-volume title publish a deliberately citation-baiting review article to juice next year's number. The metric is also a two-year window — which punishes fields where papers mature slowly (think synthetic methodology, where citations build over five to ten years) and rewards fast-moving fields like nanotech.

Self-citation matters too. Some journals encourage authors to cite recent papers from the same journal during revision. Clarivate suppresses journals caught doing this aggressively, but mild patterns still inflate numbers. And — this one bites grad students — impact factor measures the journal, not your paper. Your individual paper might never be cited even if it lands in a 20+ IF venue.

There's a deeper problem too: the numerator and denominator don't always count the same things. Clarivate counts citations to everything in the numerator (including editorials, news pieces, and front matter), but only counts "citable items" (original research articles and reviews) in the denominator. Journals that publish a lot of high-citation front matter can mathematically inflate their impact factor without any change in the quality of their original research. ACS journals are generally clean here, but it's worth knowing the trick exists.

If impact factor isn't enough, what should you look at? Several complementary metrics give a fuller picture, and most are free to check on the journal's homepage or via Scopus/Web of Science.

CiteScore from Scopus uses a four-year window and a broader citation pool. Numbers run slightly higher than impact factor for the same journal, but trends usually agree directionally. SJR (SCImago Journal Rank) weights citations by the prestige of the citing journal — a citation from a top-tier title counts more than one from a low-tier title.

SNIP (Source Normalized Impact per Paper) normalizes for citation potential across subject fields. And h5-index from Google Scholar measures the largest number h such that h articles from the journal in the last 5 years each have at least h citations — a robust, manipulation-resistant alternative.

For chemistry specifically, looking at all four alongside impact factor gives you the cleanest read. If a journal scores well across the board, the headline number is probably reliable. If impact factor is the outlier, dig deeper.

Here's the practical answer to "which ACS journal should I aim for?" — it depends almost entirely on what you've done. The structure cards below break the major journals into the kinds of papers they actually want, beyond just the topical scope listed on the masthead.

Pay attention to the "best fit" line in each card. Editors tell you in their cover letters what they're looking for, and the patterns are remarkably consistent year over year. ACS Nano wants a mechanism, a measurement, and an application — all three. JACS wants the cleanest version of a fundamental advance. ACS Omega wants solid, complete, reproducible work without the novelty bar.

Beyond these flagships, the ACS portfolio includes a long tail of specialty journals where strong work goes to find its natural audience. ACS Infectious Diseases (around 4.5) is a respected home for antimicrobial and chemical biology work. ACS Synthetic Biology (around 4.7) hosts metabolic engineering and synthetic biology. ACS Chemical Biology (around 4) covers chemical probes and mechanism work. These look modest next to the headliners, but their citation pace tells you these are dense, technical, well-read journals in tight communities.

One thing worth flagging before you submit anywhere — open access status affects citation rates. Gold open access journals like ACS Omega, ACS Central Science, and (since 2023) several others under ACS's transformative agreements tend to accumulate citations faster than paywalled journals, especially in international collaborations. That's part of why ACS Central Science punches above its weight on impact factor.

The flip side: APCs (article processing charges) for ACS gold OA journals range from roughly $2,500 to $5,000. Check whether your institution has a Read & Publish agreement with ACS — many R1 universities and major European institutions do, which can zero out the fee for corresponding authors. Some funding agencies (NIH, Wellcome, UKRI, ERC) explicitly cover OA fees as a grant line item. If yours does, factor that into your submission strategy from the start.

Hybrid open access (paid OA option in a subscription journal) is a different animal. It costs about the same as gold OA but doesn't always boost citation rates as much, because the journal's default state in indexers is still "subscription." If you're paying for OA, gold OA journals typically give you better value per citation.

Let's get tactical. The tabs below split the ACS portfolio into four common submission scenarios. Pick the tab that matches your situation, then look at the journals listed inside.

Then a final exam-style sanity check before you actually hit submit. Read the abstract of the three most recently accepted papers in your target journal. Are they meaningfully more impressive than yours? If so, aim lower. Meaningfully less impressive? Aim higher — or at the same tier with a stronger cover letter. About the same? You're in the right range.

One last honest observation that doesn't fit neatly anywhere else. The impact factor system isn't going away, but it's slowly losing dominance. Funders like the Wellcome Trust and major European agencies have signed DORA (the San Francisco Declaration on Research Assessment), which formally rejects using journal impact factor in hiring and grant decisions.

Some U.S. institutions are following. Slowly. What's replacing it isn't a single metric — it's a portfolio view: a few selected papers, narrative descriptions of impact, code and data availability, preprint deposits, and qualitative peer assessment. None of which fits in a single number, which is exactly the point.

Practically, this means early-career chemists should think about both systems. The legacy impact-factor system still dominates in many countries and many U.S. private institutions. The narrative-portfolio system is more common at progressive European universities and a growing number of U.S. R1s.

If you're targeting positions in both worlds, you need a CV that reads well in either framework — a small number of high-impact-factor publications anchoring the legacy view, plus a clear narrative thread connecting your body of work for the portfolio view. ChemRxiv preprints help bridge the two: they signal openness while still letting you anchor your portfolio with a strong journal placement.

Bookmarks worth keeping. The ACS Publications "Latest Articles" page updates daily, and most ACS journals now publish ASAP (As Soon As Publishable) versions weeks ahead of issue assignment. If you're tracking a competitive area, set up keyword alerts in ACS's portal or via Scopus — you'll see new methods landing weeks before your competitors notice.

Practice navigating these tools the same way you'd practice exam questions. There's real value in knowing where to look quickly, especially when a reviewer asks you to address a paper that landed two weeks ago. Run through a few ACS practice questions to keep the fundamentals sharp while you're between manuscript drafts.

The bottom line is unromantic but true. Pick a journal whose readers will care about your finding. Match your scope honestly. Use impact factor as one signal, not the deciding vote. Track CiteScore, SJR, and quartile alongside it. And remember that your most-cited paper is rarely your highest-impact-factor one — research careers are built on a portfolio of work, not on a single trophy publication. Good luck with the submission.